Risk of Fractures With Selective Serotonin-Reuptake Inhibitors or Tricyclic Antidepressants

The odds of breaking a bone are stacked against individuals using antidepressant drugs within the classes of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs).

This study assessed whether people taking medications belonging to the classes of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) have higher chances of suffering from fractures. Researchers collated data from 13 clinical studies.

Researchers observed that the likelihood of fracturing a bone was high among users of tricyclic antidepressants and selective serotonin reuptake inhibitors.This study adds to the growing body of evidence supporting the fracture-promoting effect of tricyclic antidepressants and selective serotonin reuptake inhibitors.